BioWorld

Sep. 18, 2003

CytRx Raises $8.7M, Forms Subsidiary For RNAi Efforts

Raising $8.7 million in a private placement, CytRx Corp. said it's using most of the money to form a subsidiary that will develop orally active small-molecule RNA interference drugs for obesity and Type II diabetes. (BioWorld Today) Read More

Repligen, BMS Receive Patent Ruling; More Trouble Ahead?

South Koreans Reveal 3-D Structure Of Viagra Active Site - Drug Design With Better Pharmacological Profile

Aphton Raises $22.7M, Plans FDA Filing For Cancer Drug

ICAAC

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...